>
How Do Dumb People or Corrupt People Get Elected to Top Positions?
Brand New Solar Battery With THIS Amazing Feature! EG4 314Ah Wall Mount Review
This New Forecast Just Got WAY Worse...
S3E4: The Freedom Movement Funded Its Own Prison
The day of the tactical laser weapon arrives
'ELITE': The Palantir App ICE Uses to Find Neighborhoods to Raid
Solar Just Took a Huge Leap Forward!- CallSun 215 Anti Shade Panel
XAI Grok 4.20 and OpenAI GPT 5.2 Are Solving Significant Previously Unsolved Math Proofs
Watch: World's fastest drone hits 408 mph to reclaim speed record
Ukrainian robot soldier holds off Russian forces by itself in six-week battle
NASA announces strongest evidence yet for ancient life on Mars
Caltech has successfully demonstrated wireless energy transfer...
The TZLA Plasma Files: The Secret Health Sovereignty Tech That Uncle Trump And The CIA Tried To Bury

Company milestones are starting to make the possibilities of their respective technologies, which once seemed far off, appear as though they are in reach, according to a new report.
For example, in September, Neuralink gained FDA approval to fast-track its Blindsight vision tech, while last month, Science, led by former Neuralink President Max Hodak, reported clinical trial success in restoring vision for age-related macular degeneration.
Backed by growing investor interest and regulatory support, startups like Science ($150M raised) and Neuralink ($600M raised) are advancing brain-computer vision technology, according to Yahoo/Bloomberg.
Hodak told Bloomberg: "Restoring vision to patients will be the first killer app."
Science reported that 32 of 38 patients in its study experienced significant vision improvements, reading an average of five lines lower on an eye chart, with one patient improving by nearly 12 lines.
The Yahoo/Bloomberg report says that startups restoring sight are exploring diverse approaches.
Science is developing Prima, a retinal implant offering vision improvements through an 80-minute outpatient procedure. It complements future brain-based devices and has FDA breakthrough status, like Neuralink's Blindsight.
While retinal implants show promise, some researchers aim for visual cortex implants, which could address severe retinal or optical nerve damage with greater resolution. Competing technologies, like cell therapy, are also advancing, with companies like Cellino raising significant funds.
Though sight restoration via electrodes often results in blurry flashes, patients report life-enhancing benefits. Neuralink's Blindsight aims to implant electrodes in the visual cortex, promising ambitious advancements as patient trials progress.
Neuralink President DJ Seo concluded on a podcast earlier this year. He spoke about the potential for a glasses-and-electrode system that could eventually go beyond treating blindness: "We're currently limited by our biology in terms of the wavelength that we can see. But when you have an external camera with this BCI system, you're not limited to that."
"You can have infrared, you can have UV, you can have whatever other spectrum that you want to see," he concluded.